Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

This important study shows that nutrient stress emanating from the microenvironment induces metabolic vulnerabilities in pancreatic ductal adenocarcinoma (PDAC). Using a combination of cell-based and ...

Cynaptec is a newly created private Delaware corporation which will own and develop the Company's novel drug development candidate Conjugated Psilocin TM. Lobe Sciences previously announced its ...

The total gross proceeds, if the option is fully exercised, would total US$26,000,000. Cynaptec is a newly created private Delaware corporation which will own and develop the Company's novel drug ...

Enantioselective amine-catalyzed conjugate additions of aldehydes to oxetane- and azetidine-containing nitroolefins afford γ-nitroaldehydes as key building blocks en route to spirocyclic ...

Center of Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou ...

It can be quite complicated to design the antibody (or other affinity molecule) drug conjugate complex in such a way that it retains its stability and, at the same time, is fully soluble. This is ...